ACGeneTic
The name “ACGeneTic” is derived from the four nucleotide bases that make up DNA—Adenine (A), Cytosine (C), Guanine (G), and Thymine (T)—reflecting our mission rooted in genetic science.
The First Goal
ACGeneTic Therapeutics was founded with a primary focus on developing personalized gene-editing therapies for Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B), a rare and progressive genetic disorder caused by gene mutations. However, our ultimate goal extends beyond LGMD2B—to advance precise gene-editing technologies that can be applied to a wide range of other rare genetic diseases.
Individualized Gene Therapy for Muscular Disorders
After completing our research on LGMD2B, we are committed to expanding our efforts to other types of muscular disorders and genetic diseases. We believe that the knowledge and experience gained from our work on LGMD2B will serve as a strong foundation for developing new treatments for patients with other rare conditions.
Passions & Possibility
The founder of this company is himself a patient with LGMD2B, as are his siblings. Since his diagnosis, he has been searching for a cure, but so far, no effective medicine, treatment, or therapy has been available. However, recent advancements in stem cell research and gene-editing technologies are offering new hope—with promising potential to treat LGMD2B and other muscular disorders.